Comparative Pharmacology
Head-to-head clinical analysis: DIZAC versus ESTAZOLAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIZAC versus ESTAZOLAM.
DIZAC vs ESTAZOLAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dizac is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA_A receptor, resulting in increased chloride ion influx, neuronal hyperpolarization, and inhibition of neuronal excitability.
Benzodiazepine that binds to GABA-A receptors at the alpha-1 subunit, enhancing the effect of GABA by increasing chloride ion conductance, leading to neuronal hyperpolarization and CNS depression.
10 mg IV/IM every 4-6 hours as needed; max 40 mg/day.
1-2 mg orally at bedtime.
None Documented
None Documented
Terminal elimination half-life: 2.5-4 hours in adults; prolonged in renal impairment (up to 20 hours in anuria), neonates, and elderly. Clinical context: Repeated dosing recommended every 4-6 hours.
Clinical Note
moderateEstazolam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Estazolam is combined with Fluticasone propionate."
Clinical Note
moderateEstazolam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Estazolam."
Clinical Note
moderateEstazolam + Erythromycin
"The serum concentration of Erythromycin can be increased when it is combined with Estazolam."
Clinical Note
moderateEstazolam + Cyclosporine
Terminal elimination half-life: 10-24 hours (mean ~17 hours); prolonged in elderly and hepatic impairment.
Renal (70-80% as unchanged drug and metabolites, primarily via glomerular filtration and active tubular secretion), biliary/fecal (15-20%)
Renal: ~90% as metabolites, <1% unchanged. Fecal: small amount, ~10%.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Estazolam."